Epsilon M&A Deal Report - Dreampath Diagnostics
Transaction Multiples for the Valuation of Private Companies
Halma > Dreampath Diagnostics
Announced Date : 07 July 2026
Type : Exit ,Acquisition of Majority Stake
Deal Value : Yes
Acquirer : Halma
Target: Dreampath Diagnostics
Target Country: France
Sector of activity : Software, Health, Pharmaceuticals & Biotechnology
Business Description :
> Founded in 2012 by Pablo Jordan and Valérie Wilhelm, Dreampath Diagnostics spe ...
Transaction multiples available
| EV/Sales | EV/Gross Profit | EV/EBITDA | EV/EBIT | Eq/PBT | P/E | Price to Book | |
|---|---|---|---|---|---|---|---|
| Historic | |||||||
| Current |
: Multiple available
n.s : Multiple calculated, but not significant
Rating **
Source: Epsilon Research / EMAT
Comparable Transactions
Number of EMAT Reports : (Health, Pharmaceuticals & Biotechnology) = 1293
Example of comparable transactions on EMAT (same sub-sector):
| Date | Acquirer | Target | Country | Multiples | See details |
|---|---|---|---|---|---|
| 26/01/2026 | Private group led by Sagard | Essences et Parfums | France | * | |
| 15/06/2026 | Private group med by Capza | Respire | France | * |
Source: Epsilon Research / EMAT
This report is accessible on EMAT, the reference database for private company acquisition multiples
Example of EMAT Report : click here
View Complete ReportEpsilon Research is an independent research and financial analysis bureau, and the reference source of transaction multiples for the valuation of private companies through its EMAT database.
Sectors covered by our analysts
Studies & indices published by Epsilon Research Register to receive (free) publications updates
Each EMAT Report includes the detailed analysis of the transaction: deal rationale and structure, target business lines and financials (restated), valuation multiples (calculation and analysis).
Sign up (free) to receive by e-mail updates on EMAT reports published on your preferred sector.
Subscribe to EMAT database
